| Name | Title | Contact Details |
|---|
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
Byte Me is a Sorrento, FL-based company in the Software and Internet sector.
We provide industry-leading technology to power the financial advisory experience, helping our customers thrive and grow. #financialservices #FinTech #CyberSec
Senzing delivers the first AI product for entity resolution to find who is who in data. Affordable, plug-and-play, and available as a desktop app or API.
Interpres is a Threat Informed Defense Surface Management Platform that fuses and operationalizes prioritized adversarial techniques, tactics, and procedures with your unique threat profile, your unique security stack and finished intelligence to identify coverage gaps, prioritize actions, optimize defenses and reduce risk. Interpres Security makes security performance intelligible and provable for the enterprise with a comprehensive new approach to managing the defense surface. With Interpres, security teams can take a threat-informed perspective to understand what their current tools can detect and defend against, identify gaps and inefficiencies, and iteratively improve their security posture with a data-driven and custom tailored approach.